Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Vaxcyte reported its Q4 and full-year 2024 financial results, highlighting the successful completion of the VAX-31 Phase 2 adult program. The company plans to start the VAX-31 Phase 3 study by mid-2025 and expects to release data in 2026. Additionally, Vaxcyte aims to announce data from the VAX-24 infant Phase 2 study by Q1 2025 and booster dose data by the end of 2025.
February 25, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxcyte (PCVX) completed the VAX-31 Phase 2 adult program and plans to initiate a Phase 3 study by mid-2025. The company also expects to release VAX-24 infant study data by Q1 2025.
The successful completion of the VAX-31 Phase 2 program and the upcoming Phase 3 study are positive developments for Vaxcyte, indicating progress in their product pipeline. The anticipated data releases for VAX-24 could further impact investor sentiment positively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100